The popularity of Sildenafil initially fueled a boom for major pharmaceutical companies, but recent developments present a murky outlook for those considering a stake. Off-patent versions are eroding earnings, and https://hannatrbk445189.ka-blogs.com/94661920/the-blue-pill-and-pharma-a-precarious-investment